These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33364789)

  • 1. Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function.
    Pavord ID; Siddiqui S; Papi A; Corren J; Sher LD; Bardin P; Langton D; Park HS; Rice MS; Deniz Y; Rowe P; Staudinger HW; Patel N; Ruddy M; Graham NMH; Teper A
    J Asthma Allergy; 2020; 13():701-711. PubMed ID: 33364789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline.
    Bourdin A; Virchow JC; Papi A; Lugogo NL; Bardin P; Antila M; Halpin DMG; Daizadeh N; Djandji M; Ortiz B; Jacob-Nara JA; Gall R; Deniz Y; Rowe PJ
    Respir Med; 2022 Oct; 202():106938. PubMed ID: 36087550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.
    Bourdin A; Papi AA; Corren J; Virchow JC; Rice MS; Deniz Y; Djandji M; Rowe P; Pavord ID
    Allergy; 2021 Jan; 76(1):269-280. PubMed ID: 33010038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.
    Corren J; Katelaris CH; Castro M; Maspero JF; Ford LB; Halpin DMG; Rice MS; Radwan A; Deniz Y; Rowe PJ; Teper A; Djandji M
    Eur Respir J; 2021 Oct; 58(4):. PubMed ID: 34266940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose.
    Pavord ID; Bourdin A; Papi A; Domingo C; Corren J; Altincatal A; Radwan A; Pandit-Abid N; Jacob-Nara JA; Deniz Y; Rowe PJ; Laws E; Lederer DJ; Hardin M
    Allergy; 2023 Nov; 78(11):2921-2932. PubMed ID: 37431558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
    Tohda Y; Nakamura Y; Fujisawa T; Ebisawa M; Arima K; Miyata M; Takahashi Y; Rice MS; Deniz Y; Rowe P; Patel N; Graham NMH; Teper A
    Allergol Int; 2020 Oct; 69(4):578-587. PubMed ID: 32444306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma.
    Papi A; Corren J; Castro M; Domingo C; Rogers L; Chapman KR; Jackson DJ; Daizadeh N; Pandit-Abid N; Gall R; Jacob-Nara JA; Rowe PJ; Deniz Y; Ortiz B
    Allergy; 2023 Jan; 78(1):233-243. PubMed ID: 35899469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils.
    Bleecker ER; Panettieri RA; Lugogo NL; Corren J; Daizadeh N; Jacob-Nara JA; Deniz Y; Rowe PJ; Khodzhayev A; Soler X; Ferro TJ; Hansen CN
    J Immunol Res; 2023; 2023():9943584. PubMed ID: 37901346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma.
    Pavord ID; Casale TB; Corren J; FitzGerald MJ; Deniz Y; Altincatal A; Gall R; Pandit-Abid N; Radwan A; Jacob-Nara JA; Rowe PJ; Busse WW
    J Allergy Clin Immunol Pract; 2024 Jul; 12(7):1763-1772. PubMed ID: 38555079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization.
    Corren J; Jackson DJ; Casale TB; Borish L; Rabe KF; Busse WW; Maspero JF; Jackson DJ; Daizadeh N; Altincatal A; Radwan A; Khodzhayev A; Djandji M; Jacob-Nara JA; Rowe PJ; Deniz Y
    J Asthma Allergy; 2023; 16():249-260. PubMed ID: 36915284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.
    Busse WW; Maspero JF; Rabe KF; Papi A; Wenzel SE; Ford LB; Pavord ID; Zhang B; Staudinger H; Pirozzi G; Amin N; Akinlade B; Eckert L; Chao J; Graham NMH; Teper A
    Adv Ther; 2018 May; 35(5):737-748. PubMed ID: 29725983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis.
    Busse WW; Maspero JF; Lu Y; Corren J; Hanania NA; Chipps BE; Katelaris CH; FitzGerald JM; Quirce S; Ford LB; Rice MS; Kamat S; Khan AH; Jagerschmidt A; Harel S; Rowe P; Pirozzi G; Amin N; Ruddy M; Graham NMH; Teper A
    Ann Allergy Asthma Immunol; 2020 Nov; 125(5):565-576.e1. PubMed ID: 32474156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction.
    Hanania NA; Castro M; Bateman E; Pavord ID; Papi A; FitzGerald JM; Maspero JF; Katelaris CH; Singh D; Daizadeh N; Altincatal A; Pandit-Abid N; Soler X; Siddiqui S; Laws E; Jacob-Nara JA; Rowe PJ; Lederer DJ; Hardin M; Deniz Y
    Ann Allergy Asthma Immunol; 2023 Feb; 130(2):206-214.e2. PubMed ID: 36332763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.
    Castro M; Rabe KF; Corren J; Pavord ID; Katelaris CH; Tohda Y; Zhang B; Rice MS; Maroni J; Rowe P; Pirozzi G; Amin N; Ruddy M; Akinlade B; Graham NMH; Teper A
    ERJ Open Res; 2020 Jan; 6(1):. PubMed ID: 32010719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.
    Corren J; Castro M; O'Riordan T; Hanania NA; Pavord ID; Quirce S; Chipps BE; Wenzel SE; Thangavelu K; Rice MS; Harel S; Jagerschmidt A; Khan AH; Kamat S; Maroni J; Rowe P; Lu Y; Amin N; Pirozzi G; Ruddy M; Graham NMH; Teper A
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):516-526. PubMed ID: 31521831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study.
    Guilbert TW; Tolcachier A; Fiocchi AG; Katelaris CH; Phipatanakul W; Begin P; de Mir I; Altincatal A; Gall R; Ledanois O; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
    J Asthma Allergy; 2024; 17():143-159. PubMed ID: 38476213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study.
    Guilbert TW; Murphy KR; Hamelmann E; Ross KR; Gupta A; Fiocchi A; Xia C; Gall R; Ledanois O; Radwan A; Jacob-Nara JA; Rowe PJ; Deniz Y
    J Asthma Allergy; 2024; 17():81-87. PubMed ID: 38347908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study.
    Maspero JF; Cardona G; Schonffeldt P; Tolcachier A; González-Diaz SN; Yañez A; Galvao CE; Msihid J; Gall R; Siddiqui S; Rowe PJ; Deniz Y; Jacob-Nara JA; Djandji M
    J Asthma; 2023 May; 60(5):981-990. PubMed ID: 36066123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.
    Corren J; Katelaris CH; Castro M; Maspero JF; Humbert M; Halpin DMG; Altincatal A; Pandit-Abid N; Soler X; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
    ERJ Open Res; 2023 Sep; 9(5):. PubMed ID: 37859672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.